"I joke that on face value, the APPs work for me, but I feel like I'm really working for them, because they basically do everything except for the surgery," says Andrew Y. Sun, MD.

"The final rule for 2025 poses several challenges to urology. Lobbying efforts to preserve telehealth access and the CF will continue, perhaps dragging into 2025," write Jonathan Rubenstein, MD, and ...

Management of mCSPC involves ADT combined with systemic therapies like docetaxel, abiraterone, enzalutamide, or apalutamide. These combination therapies improve overall survival and progression-free ...

"Things that were typically used to recruit younger physicians need to change because those aren't their priorities anymore," says Kari Bailey, MD. In this video, Kari Bailey, MD, recaps a key point ...

What are the next steps for this research? I think the main question is, how does PSA-directed therapy and metastasis-directed therapy affect recurrent metastasis-free survival and survival outcomes ...

Experts discuss overactive bladder and the impacts on quality of life, distinguishing OAB from BPH, and how a delayed diagnosis can worsen symptoms.

“Prostate cancer patients with life expectancies of less than 5 or 10 years were being subjected to treatments that can take up to a decade to significantly improve their chances of surviving cancer, ...

"The final rule for 2025 poses several challenges to urology. Lobbying efforts to preserve telehealth access and the CF will continue, perhaps dragging into 2025," write Jonathan Rubenstein, MD, and ...

OAB exhibits distinct pathophysiological differences in men and women, complicating diagnosis due to symptom overlap with BPH in men. Engaging patients in the diagnostic process is crucial for ...

Panelists discuss how metastatic castration-sensitive prostate cancer (mCSPC) is managed with a combination of androgen deprivation therapy, chemotherapy, and novel agents like such as abiraterone and ...

"Honestly, there really isn't another measure of sexual quality of life for females that addresses the specific concerns of the female partners of patients with prostate cancer," says Stacy Loeb, MD, ...

"When determining which code you should use, you must consider your Medicare carrier’s published rules and commercial payer processing policies," write Jonathan Rubenstein, MD, and Mark Painter.